Invega Sustenna Recall Issued for 70,000 Syringes by Johnson & Johnson

About 70,000 syringes filled with Johnson & Johnson’s antipsychotic drug Invega Sustenna have been recalled after it was discovered that some of the syringes were cracked. 

The Invega Sustenna syringe recall (pdf) was announced by Johnson & Johnson subsidiary Janssen on its website on February 11.

The cracks in the syringes, which could compromise the drug’s sterility, are completely covered by the label and are not detectable by the user.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

In addition to problems with sterility, the recalled Invega syringes could also result in patients receiving lower than expected doses of medication, although this risk is reportedly small. There have been no reports of injuries or adverse effects as a result of the cracked syringes.

The syringe recall applies to Invega Sustenna (paliperidone palmitate 234 mg) Extended-Release Injectable Suspension with NDC 50458-564-01 and lot numbers 9IBK000, 9IBK001, 9IBK002, 9IBK003, 9IBK004, 9IBK005 and 9JBK000 with expiration dates including 09/2011, 12/2011, 02/2012, 05/2012 and 12/2012. It also affects sample packages with the NDC 50458-564-03 and lot numbers 9JBK000, 9JBK001 and 9IBK000 and expiration dates of 08/2012 and 12/2011. The recall affects only the 234 mg strength version of the drug.

Invega Sustenna is a once-a-month atypical antipsychotic approved by the FDA to treat schizophrenia. Worldwide sales of Invega were $424 million in 2010.

Johnson & Johnson is asking pharmacies and health care providers to examine their inventories for the recalled syringes and discontinue distribution and use of those products. They are also being asked to forward the recall notice on to any hospitals, clinics or health care professionals to whom they may have sold the syringes.

Customers can contact Stericycle at 1-888-376-2051 for a return package in order to receive a refund or credit.

2 Comments

  • CandaceApril 13, 2012 at 6:08 pm

    I just sent a comment in and incorrectly said the broken syringe was Invega Sustenna. it was Risperdal Consta.

  • CandaceApril 13, 2012 at 5:56 pm

    Any information regarding injuries to those injecting the Invega when the syringe shatters?

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.